Nicardipine
Cardene (nicardipine) is a small molecule pharmaceutical. Nicardipine was first approved as Cardene on 1988-12-21. It is used to treat hypertension, stable angina, and variant angina pectoris in the USA. It is known to target adenosine receptor A3 and potassium voltage-gated channel subfamily A member 4.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Cardene (generic drugs available since 1996-10-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nicardipine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER | Chiesi Farmaceutici | N-019734 RX | 2008-11-07 | 1 products, RLD, RS |
| CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER | Chiesi Farmaceutici | N-019734 RX | 2008-07-31 | 1 products, RLD, RS |
| CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER | Chiesi Farmaceutici | N-019734 RX | 2008-07-31 | 1 products, RLD, RS |
| NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | Hikma Pharmaceuticals | N-022276 RX | 2016-04-07 | 2 products, RLD, RS |
| NICARDIPINE HYDROCHLORIDE | Hikma Pharmaceuticals | N-022276 RX | 2008-07-24 | 1 products, RLD, RS |
| NICARDIPINE HYDROCHLORIDE | sparc | N-078405 RX | 2009-11-17 | 1 products |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cardene iv | New Drug Application | 2022-11-22 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
284 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyslipidemias | D050171 | HP_0003119 | 4 | 2 | 5 | 10 | 3 | 24 | |
| Hypercholesterolemia | D006937 | HP_0003124 | 2 | 2 | 14 | 3 | 2 | 23 | |
| Healthy volunteers/patients | — | 7 | 1 | — | 1 | 8 | 17 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | 3 | 5 | 5 | 14 |
| Coronary disease | D003327 | — | 1 | 6 | 3 | 2 | 12 | ||
| Coronary artery disease | D003324 | I25.1 | — | 1 | 2 | 4 | 4 | 11 | |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | 5 | 2 | 3 | 10 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | 2 | 2 | 1 | 2 | 9 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 2 | — | 1 | 3 | 7 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | 1 | — | 4 | 1 | 6 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 8 | — | 5 | 15 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 6 | — | 3 | 10 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 4 | — | 1 | 6 |
| Neoplasms | D009369 | C80 | 3 | 4 | 1 | — | — | 6 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 2 | — | 2 | 4 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | 2 | — | 2 | 4 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | 2 | 1 | — | — | 4 |
| Flushing | D005483 | R23.2 | — | 1 | 1 | — | 1 | 3 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | — | 1 | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | 1 | — | 1 | 2 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 3 | — | — | 3 | 6 | |
| Heart failure | D006333 | EFO_0003144 | I50 | 2 | 3 | — | — | — | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 3 | 4 |
| Mitochondrial myopathies | D017240 | Orphanet_206966 | G71.3 | — | 1 | — | — | 3 | 4 |
| Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | 2 | 4 | |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | 2 | 2 | — | — | — | 3 |
| Inflammation | D007249 | 1 | 1 | — | — | 2 | 3 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 2 | — | — | 1 | 3 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 1 | — | — | — | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | — | — | — | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | C85.9 | 3 | — | — | — | — | 3 | |
| Multiple myeloma | D009101 | C90.0 | 1 | — | — | — | — | 1 | |
| Follicular lymphoma | D008224 | C82 | 1 | — | — | — | — | 1 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 1 | — | — | — | — | 1 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | 1 | — | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | — | — | — | — | 1 | |
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | — | 1 |
| Melanosis | D008548 | EFO_0003963 | L81.1 | 1 | — | — | — | — | 1 |
| Actinic keratosis | D055623 | L57.0 | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 6 | 6 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | — | — | — | 2 | 2 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | — | — | — | 1 | 1 | |
| Respiratory sounds | D012135 | HP_0010307 | R06.1 | — | — | — | — | 1 | 1 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | — | — | — | 1 | 1 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | — | — | — | 1 | 1 |
| Sleep deprivation | D012892 | F51.12 | — | — | — | — | 1 | 1 |
Show 35 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NICARDIPINE |
| INN | nicardipine |
| Description | Nicardipine is a racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension. It has a role as an antihypertensive agent, a calcium channel blocker, a vasodilator agent and an autophagy inhibitor. It contains a (S)-nicardipine and a (R)-nicardipine. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1 |
Identifiers
| PDB | — |
| CAS-ID | 55985-32-5 |
| RxCUI | 7396 |
| ChEMBL ID | CHEMBL1484 |
| ChEBI ID | 7550 |
| PubChem CID | 4474 |
| DrugBank | DB00622 |
| UNII ID | CZ5312222S (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,257 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,133 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more